Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimens.

Valero, Vicente; Forbes, John; Pegram, Mark D; Pienkowski, Tadeusz; Eiermann, Wolfgang; von Minckwitz, Gunter; Roche, Henri; Martin, Miguel; Crown, John; Mackey, John R; Fumoleau, Pierre; Rolski, Janusz; Mrsic-Krmpotic, Zrinka; Jagiello-Gruszfeld, Agnieszka; Riva, Alessandro; Buyse, Marc; Taupin, Henry; Sauter, Guido; Press, Michael F; Slamon, Dennis J

Valero, Vicente; Forbes, John; Pegram, Mark D; Pienkowski, Tadeusz; Eiermann, Wolfgang; von Minckwitz, Gunter; Roche, Henri; Martin, Miguel; Crown, John; Mackey, John R; Fumoleau, Pierre; Rolski, Janusz; Mrsic-Krmpotic, Zrinka; Jagiello-Gruszfeld, Agnieszka; Riva, Alessandro; Buyse, Marc; Taupin, Henry; Sauter, Guido; Press, Michael F; Slamon, Dennis J.

Affiliation

Valero V; Department of Breast Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA. vvalero@mdanderson.org

J Clin Oncol ; 29(2): 149-56, 2011 Jan 10.

Article in En | MEDLINE | ID: mdl-21115860

Subject(s)

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms / Antineoplastic Combined Chemotherapy Protocols / Gene Amplification / Receptor, ErbB-2 Type of study: Clinical_trials Limits: Female / Humans / Middle aged Language: En Journal: J Clin Oncol Year: 2011 Document type: Article Affiliation country: Country of publication:

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google